Victory Capital Management
MRVI icon

Victory Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Victory Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.8K Buy
12,147
+220
+2% +$950 ﹤0.01% 2355
2026
Q1 		$33.8K Sell
11,927
-247
-2% -$837 ﹤0.01% 2349
2025
Q4 		$39.6K Buy
12,174
+265
+2% +$892 ﹤0.01% 2352
2025
Q3 		$34.2K Sell
11,909
-857
-7% -$2.19K ﹤0.01% 2372
2025
Q2 		$30.8K Sell
12,766
-1,450
-10% -$3.05K ﹤0.01% 2416
2025
Q1 		$31.4K Sell
14,216
-82,057
-85% -$324K ﹤0.01% 2400
2024
Q4 		$525K Buy
96,273
+37,946
+65% +$244K ﹤0.01% 2024
2024
Q3 		$485K Buy
58,327
+44,180
+312% +$382K ﹤0.01% 2011
2024
Q2 		$101K Sell
14,147
-19,223
-58% -$166K ﹤0.01% 2295
2024
Q1 		$289K Sell
33,370
-77,098
-70% -$522K ﹤0.01% 2129
2023
Q4 		$724K Buy
110,468
+77,727
+237% +$502K ﹤0.01% 1856
2023
Q3 		$327K Buy
32,741
+9,151
+39% +$100K ﹤0.01% 2098
2023
Q2 		$293K Buy
23,590
+749
+3% +$10.1K ﹤0.01% 2123
2023
Q1 		$320K Buy
22,841
+10,450
+84% +$150K ﹤0.01% 2128
2022
Q4 		$177K Sell
12,391
-15,138
-55% -$238K ﹤0.01% 2286
2022
Q3 		$703K Buy
27,529
+4,151
+18% +$104K ﹤0.01% 1898
2022
Q2 		$664K Sell
23,378
-137
-0.6% -$4.34K ﹤0.01% 1939
2022
Q1 		$723K Buy
23,515
+1,904
+9% +$63.8K ﹤0.01% 1974
2021
Q4 		$906K Sell
21,611
-2,392
-10% -$96.9K ﹤0.01% 1883
2021
Q3 		$1.18M Sell
24,003
-71,514
-75% -$3.49M ﹤0.01% 1784
2021
Q2 		$3.99M Sell
95,517
-4,557
-5% -$177K ﹤0.01% 1420
2021
Q1 		$3.57M Sell
100,074
-4,953
-5% -$164K ﹤0.01% 1461
2020
Q4 		$2.95M Buy
+105,027
New +$2.92M ﹤0.01% 1390

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Victory Capital Management's MRVI Position: Q2 2026 in Review

Victory Capital Management increased its Maravai LifeSciences (MRVI) stake by 1.8% in Q2 2026, buying an estimated $950 and bringing the position to 12,147 shares worth $75.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2355.

Victory Capital Management first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.99M in Q2 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Victory Capital Management held 12,147 shares of Maravai LifeSciences worth $75.8K as of Q2 2026.
  • Victory Capital Management bought 220 Maravai LifeSciences shares in Q2 2026, an estimated $950.
  • Maravai LifeSciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2355 holding.
  • Victory Capital Management first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • Victory Capital Management's Maravai LifeSciences position peaked at $3.99M in Q2 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.